Clinical Trial Update: Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating anti-thymocyte globulin and etanercept for myelodysplastic syndromes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Myelodysplastic Myeloproliferative Neoplasms
• Myelodysplastic Syndromes

Drugs mentioned

• Etanercept (etanercept)
• anti-thymocyte globulin (antithymocyte globulin)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Leukemia, Myelodysplastic Syndromes | Phase 2 | Status: COMPLETED